Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: An open-label, multicenter, multi-arm, phase II trial

Patrick Y. Wen, Mehdi Touat, Brian M. Alexander, Ingo K. Mellinghoff, Shakti Ramkissoon, Christine S. McCluskey, Kristine Pelton, Sam Haidar, Sankha S. Basu, Sarah C. Gaffey, Loreal E. Brown, Juan Emmanuel Martinez-Ledesma, Shaofang Wu, Jungwoo Kim, Wei Wei, Mi Ae Park, Jason T. Huse, John G. Kuhn, Mikael L. Rinne, Howard ColmanNathalie Y.R. Agar, Antonio M. Omuro, Lisa M. DeAngelis, Mark R. Gilbert, John F. de Groot, Timothy F. Cloughesy, Andrew S. Chi, Thomas M. Roberts, Jean J. Zhao, Eudocia Q. Lee, Lakshmi Nayak, James R. Heath, Laura L. Horky, Tracy T. Batchelor, Rameen Beroukhim, Susan M. Chang, Azra H. Ligon, Ian F. Dunn, Dimpy Koul, Geoffrey S. Young, Michael D. Prados, David A. Reardon, W. K. Alfred Yung, Keith L. Ligon

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Fingerprint

Dive into the research topics of 'Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: An open-label, multicenter, multi-arm, phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences